Following the final showcase of our Silicon Gorge competition, we’ve launched a new profile series celebrating some of the 24 startups that reached this year’s semi-finals and final.
In this series, we’re diving into the journeys, challenges and next big steps of this year’s cohort, shining a light on the brilliant founders driving innovation across the South West.
Now we’re featuring: David Coe, CEO at CoEd Biosciences.
- What makes your solution unique?
To date, the industry has relied on magnetic beads, centrifuges and flow cytometers to separate T-cells ready for functionalisation and expansion.
Our technology is different, we copy what happens when T-cells move into lymph nodes, become activated and then migrate to the blood in search of their targets.
We put T-cells through their paces by using natural chemicals to encourage them to migrate through tiny holes. Naïve T-cells migrate into the first niche and are activated, then only activated T-cells migrate to the third niche where they expand, creating clean, motile, viable expanding T-cells. We have filed an international patent to protect our technologies.
- What are you most proud of so far?
I am very proud of my resilience, it has been tough but I’ve discovered new skills and have gone from being a solo founder to have a brilliant team around me. I’ve been proud of my own abilities to engage a team and my co-founders ability to recruit new people and build our reputation and product.
